Published in JAKSTAT on July 01, 2012
STAT5 acetylation: Mechanisms and consequences for immunological control and leukemogenesis. JAKSTAT (2013) 0.80
Inhibition of STAT5: a therapeutic option in BCR-ABL1-driven leukemia. Oncotarget (2014) 0.80
Persistent STAT5 activation in myeloid neoplasms recruits p53 into gene regulation. Oncogene (2014) 0.78
Chronic Inhibition of STAT3/STAT5 in Treatment-Resistant Human Breast Cancer Cell Subtypes: Convergence on the ROS/SUMO Pathway and Its Effects on xCT Expression and System xc- Activity. PLoS One (2016) 0.75
Granulocyte colony-stimulating factor receptor signaling in severe congenital neutropenia, chronic neutrophilic leukemia, and related malignancies. Exp Hematol (2016) 0.75
O-GlcNAcylation of STAT5 controls tyrosine phosphorylation and oncogenic transcription in STAT5-dependent malignancies. Leukemia (2017) 0.75
Concepts in sumoylation: a decade on. Nat Rev Mol Cell Biol (2007) 11.48
Nonredundant roles for Stat5a/b in directly regulating Foxp3. Blood (2007) 4.50
The JAK-STAT pathway at twenty. Immunity (2012) 4.41
Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates. Cancer Cell (2008) 4.06
Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int J Biochem Cell Biol (2008) 3.56
Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation. Blood (2006) 2.38
Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia. EMBO Mol Med (2010) 2.23
The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling. Nat Struct Mol Biol (2011) 2.20
High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood (2011) 2.08
A phosphorylation-acetylation switch regulates STAT1 signaling. Genes Dev (2009) 1.98
Epigenetic repression of the Igk locus by STAT5-mediated recruitment of the histone methyltransferase Ezh2. Nat Immunol (2011) 1.59
Conditional deletion of STAT5 in adult mouse hematopoietic stem cells causes loss of quiescence and permits efficient nonablative stem cell replacement. Blood (2009) 1.58
Critical requirement for Stat5 in a mouse model of polycythemia vera. Blood (2011) 1.48
Biology and significance of the JAK/STAT signalling pathways. Growth Factors (2012) 1.29
The role of Stat5 transcription factors as tumor suppressors or oncogenes. Biochim Biophys Acta (2010) 1.26
STAT5 requires the N-domain for suppression of miR15/16, induction of bcl-2, and survival signaling in myeloproliferative disease. Blood (2009) 1.17
Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade. Blood (2008) 1.16
Phosphorylation-acetylation switch in the regulation of STAT1 signaling. Mol Cell Endocrinol (2009) 1.13
Stat1 and SUMO modification. Blood (2006) 1.12
SUMO-specific protease 1 is critical for early lymphoid development through regulation of STAT5 activation. Mol Cell (2012) 1.11
The Jak/STAT pathway. Cold Spring Harb Perspect Biol (2012) 1.11
Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V. Am J Pathol (2009) 1.06
Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformation. Blood (2010) 1.04
Small molecule STAT5-SH2 domain inhibitors exhibit potent antileukemia activity. J Med Chem (2012) 1.03
Acetylation modulates prolactin receptor dimerization. Proc Natl Acad Sci U S A (2010) 1.01
Evolution of JAK-STAT pathway components: mechanisms and role in immune system development. PLoS One (2012) 0.94
p16INK4a deficiency promotes IL-4-induced polarization and inhibits proinflammatory signaling in macrophages. Blood (2011) 0.94
Dynamically regulated sumoylation of HDAC2 controls p53 deacetylation and restricts apoptosis following genotoxic stress. J Mol Cell Biol (2012) 0.90
Histone deacetylase inhibitors block IFNγ-induced STAT1 phosphorylation. Cell Signal (2012) 0.88
Serine phosphorylation of the Stat5a C-terminus is a driving force for transformation. Front Biosci (Landmark Ed) (2011) 0.84
Nonredundant roles for Stat5a/b in directly regulating Foxp3. Blood (2007) 4.50
Autocrine PDGFR signaling promotes mammary cancer metastasis. J Clin Invest (2006) 2.68
Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation. Blood (2006) 2.38
Impairment of hepatic growth hormone and glucocorticoid receptor signaling causes steatosis and hepatocellular carcinoma in mice. Hepatology (2011) 2.33
Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia. EMBO Mol Med (2010) 2.23
Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia (2005) 2.18
High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood (2011) 2.08
STAT1 acts as a tumor promoter for leukemia development. Cancer Cell (2006) 2.00
Reduced lymphomyeloid repopulating activity from adult bone marrow and fetal liver of mice lacking expression of STAT5. Blood (2002) 1.96
TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. Cancer Discov (2013) 1.81
Epidermal growth factor receptor signaling synergizes with Hedgehog/GLI in oncogenic transformation via activation of the MEK/ERK/JUN pathway. Cancer Res (2009) 1.78
PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. Nat Med (2012) 1.67
p19(ARF) /p14(ARF) controls oncogenic functions of signal transducer and activator of transcription 3 in hepatocellular carcinoma. Hepatology (2011) 1.60
Macrophages and neutrophils are the targets for immune suppression by glucocorticoids in contact allergy. J Clin Invest (2007) 1.51
Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias. Blood (2006) 1.50
Signal transducer and activator of transcription 3 activation promotes invasive growth of colon carcinomas through matrix metalloproteinase induction. Neoplasia (2007) 1.49
Direct glucocorticoid receptor-Stat5 interaction in hepatocytes controls body size and maturation-related gene expression. Genes Dev (2007) 1.45
A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis. Cancer Cell (2013) 1.37
Apoptosis protection by the Epo target Bcl-X(L) allows factor-independent differentiation of primary erythroblasts. Curr Biol (2002) 1.37
Stat5 regulates cellular iron uptake of erythroid cells via IRP-2 and TfR-1. Blood (2008) 1.31
Glucocorticoid receptor function in hepatocytes is essential to promote postnatal body growth. Genes Dev (2004) 1.30
Epidermal loss of JunB leads to a SLE phenotype due to hyper IL-6 signaling. Proc Natl Acad Sci U S A (2009) 1.20
Stat5 activation enables erythropoiesis in the absence of EpoR and Jak2. Blood (2008) 1.20
STAT5 requires the N-domain to maintain hematopoietic stem cell repopulating function and appropriate lymphoid-myeloid lineage output. Exp Hematol (2007) 1.19
STAT5 requires the N-domain for suppression of miR15/16, induction of bcl-2, and survival signaling in myeloproliferative disease. Blood (2009) 1.17
Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade. Blood (2008) 1.16
Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens. J Immunol (2008) 1.15
STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia. Oncotarget (2012) 1.12
JunB inhibits proliferation and transformation in B-lymphoid cells. Blood (2003) 1.10
Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V. Am J Pathol (2009) 1.06
Stat5 promotes survival of mammary epithelial cells through transcriptional activation of a distinct promoter in Akt1. Mol Cell Biol (2010) 1.05
The different functions of Stat5 and chromatin alteration through Stat5 proteins. Front Biosci (2008) 1.05
Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformation. Blood (2010) 1.04
Disruption of the growth hormone--signal transducer and activator of transcription 5--insulinlike growth factor 1 axis severely aggravates liver fibrosis in a mouse model of cholestasis. Hepatology (2010) 1.00
Growth-hormone-induced signal transducer and activator of transcription 5 signaling causes gigantism, inflammation, and premature death but protects mice from aggressive liver cancer. Hepatology (2012) 0.97
The dark and the bright side of Stat3: proto-oncogene and tumor-suppressor. Front Biosci (Landmark Ed) (2009) 0.96
A role for STAT5A/B in protection of peripheral T-lymphocytes from postactivation apoptosis: insights from gene expression profiling. Cytokine (2006) 0.94
Hepatic growth hormone and glucocorticoid receptor signaling in body growth, steatosis and metabolic liver cancer development. Mol Cell Endocrinol (2012) 0.93
Promising new sources for pluripotent stem cells. Stem Cell Rev (2010) 0.91
STAT3 controls matrix metalloproteinase-1 expression in colon carcinoma cells by both direct and AP-1-mediated interaction with the MMP-1 promoter. Biol Chem (2011) 0.90
A detailed protocol for bacterial artificial chromosome recombineering to study essential genes in stem cells. Methods Mol Biol (2008) 0.90
A novel germline JAK2 mutation in familial myeloproliferative neoplasms. Am J Hematol (2014) 0.89
Jak1 deficiency leads to enhanced Abelson-induced B-cell tumor formation. Blood (2003) 0.87
Diverging fates of cells of origin in acute and chronic leukaemia. EMBO Mol Med (2012) 0.86
Enterocyte STAT5 promotes mucosal wound healing via suppression of myosin light chain kinase-mediated loss of barrier function and inflammation. EMBO Mol Med (2012) 0.86
Sensitized phenotypic screening identifies gene dosage sensitive region on chromosome 11 that predisposes to disease in mice. EMBO Mol Med (2011) 0.84
Ischemic brain injury: a consortium analysis of key factors involved in mesenchymal stem cell-mediated inflammatory reduction. Arch Biochem Biophys (2013) 0.84
Serine phosphorylation of the Stat5a C-terminus is a driving force for transformation. Front Biosci (Landmark Ed) (2011) 0.84
SIAH2 antagonizes TYK2-STAT3 signaling in lung carcinoma cells. Oncotarget (2014) 0.83
The first European interdisciplinary ewing sarcoma research summit. Front Oncol (2012) 0.82
Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy. Haematologica (2014) 0.82
The inhibition of stat5 by a Peptide aptamer ligand specific for the DNA binding domain prevents target gene transactivation and the growth of breast and prostate tumor cells. Pharmaceuticals (Basel) (2013) 0.79
Erratum: STAT3 regulated ARF expression suppresses prostate cancer metastasis. Nat Commun (2015) 0.78
A mouse model to identify cooperating signaling pathways in cancer. Nat Methods (2012) 0.76
Reply: To PMID 21725989. Hepatology (2013) 0.75
Variants in STAT5B associate with serum TC and LDL-C levels. J Clin Endocrinol Metab (2011) 0.75
A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis. Cancer Cell (2016) 0.75
Steering of carcinoma progression by the YIN/YANG interaction of STAT1/STAT3. Biosci Trends (2017) 0.75